Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.69 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440511 | 0.88 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA | |
| SCHEMBL455553 | 0.84 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1ALDH1A1MAPTKMT2A | |
| Elesclomol SCHEMBL313745 | 0.83 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA | |
| SCHEMBL13943131 | 0.82 | HSP90AA1 (0.84) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA | |
| Elesclomol SCHEMBL2819576 | 0.81 | HSP90AA1 (0.97) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA | |
| SCHEMBL13943338 | 0.80 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA | |
| SCHEMBL453297 | 0.79 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15158087 | 0.78 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA | |
| SCHEMBL12808820 | 0.78 | HSP90AA1 (0.84) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA | |
| SCHEMBL12354384 | 0.77 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | claimed |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8729111-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729111-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729111-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8497272-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110245262-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-10-06 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| WO-2008024302-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | HSP90AA1 4700/4885HSP90AB1 4438/4885ALDH1A1 2245/4885 |
| US-20120065235-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | HSP90AA1 6/4885HSP90AB1 1/4885ALDH1A1 690/4885 |
| US-20110245262-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | HSP90AA1 6/4885HSP90AB1 1/4885ALDH1A1 690/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | HSP90AA1 4757/4885HSP90AB1 4532/4885ALDH1A1 2082/4885 |
| US-20140342999-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | HSP90AA1 6/4885HSP90AB1 1/4885ALDH1A1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.